Skip to main content
OpenTrials

Clinical trial condition

Paroxysmal Nocturnal Hemoglobinuria

Explore clinical trials studying Paroxysmal Nocturnal Hemoglobinuria. Study availability and eligibility vary by location and protocol.

92 public trials 12 recruiting studies
Refine in advanced search Browse all conditions

Paroxysmal Nocturnal Hemoglobinuria trial results

Completed

Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT02534909

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Novartis Investigative Site Brno-Bohunice, Czech Republic, Czechia
  • Novartis Investigative Site Fukushima, Japan
  • Novartis Investigative Site Isehara, Kanagawa, Japan
  • Novartis Investigative Site Suita, Osaka, Japan
View Trial Details
Completed

Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

NCT04469465

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +8 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Weston, Florida, United States
  • Research Site Chicago, Illinois, United States
  • Research Site Kalamazoo, Michigan, United States
View all 62 locations
View Trial Details
Completed

Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy

NCT04811716

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Prince of Wales Hospital Hong Kong, New Territories
  • D l Pesti Centrumk rh z Orsz gos Hematol giai s Infektol giai Int zet Budapest, Nagyvárad Tér 1, Hungary
  • Hospital Miri Miri, Sarawak, Malaysia
  • Hospital Sibu Sibu, Sarawak, Malaysia
View all 13 locations
View Trial Details
Completed

Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

NCT03748823

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Liverpool, Australia
  • Research Site Parkville, Australia
  • Research Site Vienna, Austria
View all 51 locations
View Trial Details
Completed

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT03896152

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +8 more
Locations
  • Novartis Investigative Site Kota Kinabalu, Sabah, Malaysia
  • Novartis Investigative Site Singapore
  • Novartis Investigative Site Seoul, South Korea
  • Novartis Investigative Site Seoul, South Korea
View Trial Details
Completed

A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria

NCT04058158

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Fortis Memorial Research Institute Gurgaon, Haryana, India
  • Post Graduate Institute of Medical Education and Research (PGIMER) Chandigarh, India
  • Apollo Hospitals International Limited Chennai, India
  • Amrita Institute of Medical Sciences and Research Centre Kochi, India
View all 27 locations
View Trial Details

Related conditions